Dabigatran (ethyl ester)
Code | Size | Price |
---|
TAR-T15046-5mg | 5mg | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T15046-10mg | 10mg | £144.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T15046-25mg | 25mg | £204.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T15046-50mg | 50mg | £304.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T15046-100mg | 100mg | £438.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T15046-200mg | 200mg | £585.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Dabigatran ethyl ester is an emerging oral anticoagulant and a direct inhibitor of thrombin activity.
CAS:
429658-95-7
Formula:
C27H29N7O3
Molecular Weight:
499.575
Pathway:
Proteases/Proteasome
Purity:
0.98
SMILES:
CCOC(=O)CCN(C(=O)c1ccc2n(C)c(CNc3ccc(cc3)C(N)=N)nc2c1)c1ccccn1
Target:
Thrombin
References
Simon Michaelis, Anett Marais, Anna K. Schrey, et al. Dabigatran and Dabigatran Ethyl Ester: Potent Inhibitors of Ribosyldihydronicotinamide Dehydrogenase (NQO2). J. Med. Chem., 2012, 55 (8):3934-3944
Santiago Redondo, Maria-Paz Mart?nez, Marta Ramajo, et al. Pharmacological basis and clinical evidence of dabigatran therapy. J Hematol Oncol. 2011; 4: 53.
Preetpal Singh Sidhu,Aiye Liang, Akul Y. Mehta,et al. Rational Design of Potent, Small, Synthetic Allosteric Inhibitors of Thrombin. J Med Chem. 2011; 54(15): 5522-5531.
Dabigatran
Stefan Blech, Thomas Ebner, Eva Ludwig-Schwellinger,et al. The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans. DMD ,2008 , 36 (2) 386-399